TAK - Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
2024-06-24 01:43:14 ET
Summary
- Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings.
- ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025.
- Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon.
- An updated analysis of Astria Therapeutics follows in the paragraphs below.
Today, we are going to peak in on Astria Therapeutics, Inc. ( ATXS ) for the first time since early in 2023. This clinical stage biotech firm used to be known as Catabasis Pharmaceuticals, Inc., but changed its name to its current form in 2021. We concluded our initial article around Astria with a recommendation to avoid the shares for now....
Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field